CRYSTALLINE AND NON-CRYSTALLINE FORMS OF SGLT2 INHIBITORS
The present invention provides amorphous forms and the crystalline complexes of SGLT2 inhibitors as a novel material, in particular in pharmaceutically acceptable form. The crystalline forms of SGLT2 inhibitor canagliflozin are designated as Forms CS1, CS2, CS3, CS4 and CS5.
-
Paragraph 0072-0073
(2013/09/26)
More Articles about upstream products of 1432187-89-7